| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 3.759.364 | 4.277.891 | 4.369.891 | 4.601.181 | 4.814.693 | 5.004.548 | 5.233.823 | 6.842.116 | 7.642.393 | 7.722.322 |
| Total Income - EUR | 3.789.666 | 4.234.937 | 4.386.028 | 4.635.024 | 4.830.364 | 5.051.887 | 5.342.164 | 6.852.669 | 7.954.822 | 8.277.136 |
| Total Expenses - EUR | 3.536.494 | 3.674.494 | 3.775.498 | 4.052.735 | 4.311.286 | 4.496.599 | 4.954.886 | 6.239.984 | 6.948.113 | 7.029.338 |
| Gross Profit/Loss - EUR | 253.172 | 560.442 | 610.530 | 582.289 | 519.078 | 555.288 | 387.278 | 612.685 | 1.006.710 | 1.247.798 |
| Net Profit/Loss - EUR | 218.927 | 482.512 | 519.794 | 502.802 | 443.527 | 481.963 | 334.272 | 518.821 | 865.010 | 1.068.800 |
| Employees | 47 | 47 | 43 | 47 | 45 | 46 | 48 | 48 | 48 | 46 |
Check the financial reports for the company - Tis Farmaceutic S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 755.537 | 790.291 | 888.205 | 1.062.075 | 1.324.986 | 1.311.943 | 1.170.861 | 1.791.917 | 1.707.117 | 1.529.779 |
| Current Assets | 1.714.657 | 1.911.165 | 2.035.845 | 1.680.100 | 1.780.801 | 1.840.613 | 2.265.371 | 2.855.414 | 2.829.382 | 2.797.958 |
| Inventories | 389.600 | 373.227 | 413.892 | 444.479 | 452.932 | 476.016 | 594.077 | 853.148 | 936.440 | 1.118.559 |
| Receivables | 652.306 | 741.926 | 788.233 | 847.400 | 844.289 | 749.317 | 893.279 | 1.153.093 | 1.319.766 | 1.221.407 |
| Cash | 672.751 | 796.013 | 833.720 | 388.222 | 483.579 | 615.280 | 778.015 | 849.173 | 573.176 | 457.992 |
| Shareholders Funds | 1.792.540 | 2.010.380 | 2.021.809 | 1.659.241 | 1.835.370 | 1.978.493 | 2.268.890 | 2.591.972 | 1.644.881 | 1.844.313 |
| Social Capital | 20.247 | 20.041 | 19.702 | 19.340 | 18.966 | 18.606 | 18.194 | 18.250 | 18.195 | 18.093 |
| Debts | 679.152 | 692.972 | 904.054 | 1.099.147 | 1.297.012 | 1.179.521 | 1.166.288 | 2.056.755 | 2.893.096 | 2.500.291 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "2120 - 2120" | |||||||||
| CAEN Financial Year |
2120
|
|||||||||
Comments - Tis Farmaceutic S.r.l.